Phase 1 Pulmonary Hypertension Trial, Recruiting NCT06872112 Sponsor: Joseph C. Wu Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Phase 1 Pulmonary Hypertension Trial, Recruiting

NCT06872112
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 75 years old.
  • People who have a certain level of physical limitation related to their condition (WHO functional class I, II, or III) even after already trying the maximum tolerated doses of 2 or more approved treatments for their condition, such as specific types of medications used to treat pulmonary hypertension (confirm with trial site).

Who may not be able to join:

  • People who have other serious health conditions alongside their current condition, as decided by the study doctor.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Joseph C. Wu
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
1 January 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants with treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov